[Cytostatic therapy of lymphogranulomatosis].
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003556:Cystitis / Q000139:chemically induced; D003609:Dactinomycin / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007239:Infections / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013997:Time Factors; D014228:Triaziquone / Q000627:therapeutic use; D014265:Triethylenemelamine / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D002699:Chlorambucil; D003609:Dactinomycin; D011344:Procarbazine; D014747:Vinblastine; D003520:Cyclophosphamide; D014228:Triaziquone; D014265:Triethylenemelamine
Zytostatische Therapie der Lymphogranulomatose.